Paloma Partners’s Abivax ABVX Stock Holding History

Paloma Partners’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-95,130	Closed	-$728K	–	78
2025 Q2	$728K	Buy	95,130 +56,681	+147%	+$369K	0.11%	84
2025 Q1	$240K	Buy	+38,449	New	+$260K	0.03%	107

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Paloma Partners's ABVX Position: Q3 2025 in Review

Paloma Partners sold out of Abivax (ABVX) in Q3 2025, closing a stake of 95,130 shares — an estimated $728K sold.

Paloma Partners first reported a position in ABVX in Q1 2025 and held it in 2 quarters. The position peaked at $728K in Q2 2025. 165 funds tracked by Wall St. Rank hold ABVX as of Q3 2025.

Paloma Partners reported no remaining Abivax position as of Q3 2025 after selling out during the quarter.
Paloma Partners sold 95,130 Abivax shares in Q3 2025, an estimated $728K.
Paloma Partners first reported a position in Abivax in Q1 2025 and held it in 2 quarters.
Paloma Partners's Abivax position peaked at $728K in Q2 2025.
165 funds tracked by Wall St. Rank held Abivax as of Q3 2025.

Based on Paloma Partners's 13F filing for Q3 2025, filed 14 Nov 2025.